Current developments in peritoneal glucose transport and sodium-glucose co-transporter 2 inhibitors during peritoneal dialysis
As a novel widely used drug, sodium-glucose co-transporter (SGLT) 2 inhibitor may lower blood glucose in type 2 diabetics through blocking SGLT2 to curtain glucose reabsorption in proximal renal tubular cells. At the same time, this drug may bring significant renal and cardiovascular benefits to bot...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Book |
| Published: |
Editorial Department of Journal of Clinical Nephrology,
2023-11-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_ab6017f8380c40c58b4c9e020a70ff5c | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Fan Yang |e author |
| 700 | 1 | 0 | |a Cong-hui Liu |e author |
| 700 | 1 | 0 | |a Xiao-qi Wang |e author |
| 700 | 1 | 0 | |a Xiao-jing Liu |e author |
| 700 | 1 | 0 | |a Ya-nan Shi |e author |
| 700 | 1 | 0 | |a Zhong-xin Li |e author |
| 245 | 0 | 0 | |a Current developments in peritoneal glucose transport and sodium-glucose co-transporter 2 inhibitors during peritoneal dialysis |
| 260 | |b Editorial Department of Journal of Clinical Nephrology, |c 2023-11-01T00:00:00Z. | ||
| 500 | |a 1671-2390 | ||
| 500 | |a 10.3969/j.issn.1671-2390.2023.11.010 | ||
| 520 | |a As a novel widely used drug, sodium-glucose co-transporter (SGLT) 2 inhibitor may lower blood glucose in type 2 diabetics through blocking SGLT2 to curtain glucose reabsorption in proximal renal tubular cells. At the same time, this drug may bring significant renal and cardiovascular benefits to both diabetics and non-diabetics. Human peritoneal mesothelial cells (HPMCs) from peritoneal dialysis (PD) patients can express SGLT. Studies of SGLT2 inhibitors in PD have been reported in in vitro or animal experiments. Using SGLT2 inhibitors in PD patients can reduce peritoneal glucose absorption and delay the progress of peritoneal fibrosis. At the same time, prolonged use of peritoneum and maintenance of transport function are conducive to ensuring dialysis adequacy and optimizing the prognosis. However, application of SGLT2 inhibitors during PD has not attracted extensive attention. This review focused upon the developments of peritoneal glucose metabolism and SGLT2 inhibitors during PD. | ||
| 546 | |a ZH | ||
| 690 | |a sodium-glucose transport proteins | ||
| 690 | |a peritoneal dialysis | ||
| 690 | |a peritoneal mesothelial cells | ||
| 690 | |a glucose transport | ||
| 690 | |a Internal medicine | ||
| 690 | |a RC31-1245 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Linchuang shenzangbing zazhi, Vol 23, Iss 11, Pp 946-950 (2023) | |
| 787 | 0 | |n http://www.lcszb.com/cn/article/doi/10.3969/j.issn.1671-2390.2023.11.010 | |
| 787 | 0 | |n https://doaj.org/toc/1671-2390 | |
| 856 | 4 | 1 | |u https://doaj.org/article/ab6017f8380c40c58b4c9e020a70ff5c |z Connect to this object online. |